A Study of Quabodepistat‑containing Regimens for the Treatment of Drug‑resistant Pulmonary Tuberculosis

Sponsor ID
323-201-00013
Clinicaltrials.gov ID
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
Recruiting
Sponsor ID
323-201-00013

Study Summary

This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or multidrug-resistant pulmonary tuberculosis.

Participants are assigned to 1 of 2 cohorts based on fluoroquinolone susceptibility. In the fluoroquinolone-susceptible cohort, participants are randomized 1:1 to receive either a 4-month experimental regimen of bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin. In the fluoroquinolone-resistant cohort, participants are randomized 3:1 to receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid.

A total of approximately 532 participants are planned, including 432 participants in the fluoroquinolone-susceptible cohort and approximately 100 participants in the fluoroquinolone-resistant cohort. The primary efficacy endpoint is the proportion of participants with an unfavorable outcome by 12 months post-randomization. Prespecified agency-specific definitions are used for the classification of regimen changes, sputum culture conversion, relapse, and reinfection. All unfavorable outcome events will be confirmed by a blinded Endpoint Adjudication Committee.

Additional Study Details

Phase
Phase 3
Study Drug
Drug: Bedaquiline
Type
Interventional
Masking
None (Open Label)
Estimated Enrollment
532
Additional Study Details

Inclusion and Exclusion Criteria

Inclusion Criteria

  • 1. Able to provide written informed consent prior to initiation of any trial-related procedures or treatments, and able, in the opinion of the investigator, to comply with all trial requirements (if under 18 years of age: participant assent AND parent/legal guardian consent are required).
  • 2. Male or female participants aged ≥14 years at screening.

Exclusion Criteria

  • 1. Known or suspected resistance to any drugs administered in the treatment interventions (bedaquiline \[BDQ\], pretomanid \[PMD\], linezolid \[LZD\], or quabodepistat \[QBS\]) or the respective drug classes, confirmed by laboratory testing or based on epidemiologic history (e.g., known source case with resistance).
  • 2. Prior treatment for drug-resistant TB, except where the study Medical Monitor confirms an adequate washout period for prior medications.

Locations

Location
Status
Location
Capital Medical University - Beijing Chest Hospital
Beijing, Beijing Municipality, China, 101100
Status
Recruiting
Location
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province
Fuzhou, Fujian, China, 350008
Status
Recruiting
Location
The Third People's Hospital of Shenzhen
Shenzhen, Guangdong, China, 518112
Status
Recruiting
Location
Wuhan Institute of Tuberculosis Control (Wuhan Pulmonary Hospital)
Wuhan, Hubei, China, 430032
Status
Recruiting
Location
The Second Hospital of Nanjing
Nanjing, Jiangsu, China, 210003
Status
Recruiting
Location
Shandong Public Health Clinical Center
Jinan, Shandong, China, 250102
Status
Recruiting
Showing {first} - {last} of {total} Results